You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: March 28, 2024

Litigation Details for AstraZeneca AB v. Mylan Pharmaceuticals Inc. (N.D.W. Va. 2018)


✉ Email this page to a colleague

« Back to Dashboard


Small Molecule Drugs cited in AstraZeneca AB v. Mylan Pharmaceuticals Inc.
The small molecule drug covered by the patents cited in this case is ⤷  Try a Trial .

Details for AstraZeneca AB v. Mylan Pharmaceuticals Inc. (N.D.W. Va. 2018)

Date Filed Document No. Description Snippet Link To Document
2018-10-12 1 Complaint (NOT for attorney use) expiration of U.S. Patent Nos. 7,759,328 (“the ‘328 patent”), 8,143,239 (“the ‘239 patent”), 8,575,137 (… The Patents-in-Suit 16. United States Patent No. 7,759,328 (“the ‘328 patent”), entitled…Exhibit A - Patent Information, # 2 Exhibit B - Patent Information, # 3 Exhibit C - Patent Information…of the ‘328 patent. 18. United States Patent No. 8,143,239 (“the ‘239 patent”), entitled…of the ‘239 patent. 20. United States Patent No. 8,575,137 (“the ‘137 patent”), entitled External link to document
2020-08-12 317 Memorandum & Opinion “the ’239 patent”), 8,575,137 (“the ’137 patent”), and the 10,166,247 (“the ’247 patent) (collectively…’328 patent, col. 1:21-24; ’239 patent, col. 1:25-28; ’137 patent, col. 1:26-30; ’247 patent, col.…328 patent, col. 1:46; ’239 patent, col. 1:49; ’137 patent, col. 1:48; ’247 patent, …‘328 patent, col. 2:17-21; ’239 patent, col. 2:22-26; ’137 patent, col. 2:18-22; ’247 patent, col.…Specifically, the patents at issue are U.S. Patent Nos. 7,759,328 (“the ’328 patent”), 8,143,239 External link to document
2021-03-02 431 Memorandum & Opinion infringement claims for U.S. Patent No. 10,166,247 (the “’247 patent”) (Dkt. No. 89), and deleted…States Patent No. 8,143,239 (“the ’239 Patent”); and claims 10 and 19 of United States Patent No. 8,575,137…History of Patents-In-Suit The Patent and Trademark Office (“PTO”) issued the patents-in- suit…, 13, and 14 of United States Patent No. 7,759,328 (“the ’328 Patent”); claims 12, 13, 18, and 19 …8,575,137 (“the ’137 Patent”) (collectively, “the asserted claims” or the “patents-in-suit”) are External link to document
2022-03-30 533 Status Report of trial to invalidity of U.S. Patent 10,166,247 (“the ’247 patent”) and are negotiating a stipulation…247 patent. Mylan has always and continues to maintain its defense that the ’247 patent is … is permitted to assert obviousness of the ’247 patent. AstraZeneca’s position is that law of the …nonobviousness as to the claims of the ’247 patent, all of which are directed to compositions comprising…relitigating obviousness of similar claims in related patent); Smith Int’l v. Hughes Tool, 759 F.2d 1572 External link to document
2022-04-07 539 Stipulation and Order Circuit Patents”); and 10,166,247 (“’247 patent) (together with the Federal Circuit Patents, the ….S. Patent Nos. 7,759,328 (“’328 patent”); 8,143,239 (“’239 patent”); 8,575,137 (“’137 patent”) (collectively…of the patents-in-suit, specifically, claims 1, 4, 5, 7, 9, 10, 13 and 14 of the ’328 patent (“the …the ’239 patent (“the ’239 Asserted Claims”); claims 1-6, 9, 10 and 13-53 of the ’137 patent (“the ’…, 13, and 14 of the ʼ328 patent; claims 12, 13, 18, and 19 of the ’239 patent; and claims 10 and 19 External link to document
2022-05-11 564 Stipulation current assignee and owner of U.S. Patent No. 10,166,247 (“the ’247 patent”). …–6 of the ’247 patent. III. THE ’247 PATENT 13. The ’247 patent is entitled “Composition…States Patent and Trademark Office (“PTO”) on January 1, 2019. 14. The ’247 patent issued…. 15. The ’247 patent claims priority to Swedish patent application 0200312 (the “312 …the United States. 8. The ’247 patent was submitted to FDA by AstraZeneca to be listed External link to document
2022-11-09 606 Memorandum & Opinion claims 2 and 3 of United States Patent No. 10,166,247 (“the ’247 patent”) are valid and enforceable. …United States Patent Nos. 7,759,328 (“the ’328 patent”); 8,143,239 (“the ’239 patent”); 8,575,137 …’247 patent, but does not infringe the Previously Tried Patents or claim 4 of the ’247 patent. Id.…8,575,137 (“the ’137 patent”); and 7,967,011 (“the ’011 patent”) (1:19CV203, Dkt. No. 1). Thereafter, AstraZeneca… related to the ’011 patent and to add claims related to the ’247 patent (Dkt. Nos. 89, 91). External link to document
>Date Filed >Document No. >Description >Snippet >Link To Document

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.